Manage Tickers

Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current
Analyst Rating Guide

News

Back

Medifast Q3 expected to be more than $(0.60) vs $(0.30) Est; Sees Q3 Sales $70.000M-$90.000M vs $93.800M Est

Author: Benzinga Newsdesk | August 04, 2025 03:08pm
Medifast (NYSE:MED) Q3 expected to be more than $(0.60) vs $(0.30) Est. sees Q3 sales of $70.000 million-$90.000 million vs $93.800 million analyst estimate.

Posted In: MED


CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist